MA50655B1 - Sels de dérivés de pyrrolotriazine utiles en tant qu'inhibiteurs de tam - Google Patents

Sels de dérivés de pyrrolotriazine utiles en tant qu'inhibiteurs de tam

Info

Publication number
MA50655B1
MA50655B1 MA50655A MA50655A MA50655B1 MA 50655 B1 MA50655 B1 MA 50655B1 MA 50655 A MA50655 A MA 50655A MA 50655 A MA50655 A MA 50655A MA 50655 B1 MA50655 B1 MA 50655B1
Authority
MA
Morocco
Prior art keywords
salts
derivatives useful
pyrrolotriazine derivatives
phenyl
inhibitors
Prior art date
Application number
MA50655A
Other languages
English (en)
Other versions
MA50655A (fr
Inventor
Zhongjiang Jia
Jiacheng Zhou
Yongzhong Wu
Yongchun Pan
Qun Li
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of MA50655A publication Critical patent/MA50655A/fr
Publication of MA50655B1 publication Critical patent/MA50655B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne des formes de sel de n-(4-(4-amino-7-(1- isobutyrylpipéridin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phényl)-1- isopropyl-2,4-dioxo-3-(pyridin-2-yl)-1,2,3,4-tetrahydropyrimidine-5- carboxamide (i) et de n-(4-(4-amino-7-(1-isobutyrylpipéridin-4-yl) pyrrolo[1,2-f][1,2,4]triazin-5-yl)phényl)-1-isopropyl-2,4-dioxo-3- phényl-1,2,3,4-tetrahydropyrimidine-5-carboxamide (ii), qui sont utiles en tant qu'inhibiteurs de kinases tam, ainsi que des procédés et des intermédiaires associés à celles-ci.
MA50655A 2017-09-27 2018-09-26 Sels de dérivés de pyrrolotriazine utiles en tant qu'inhibiteurs de tam MA50655B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762564070P 2017-09-27 2017-09-27
US201862714196P 2018-08-03 2018-08-03
PCT/US2018/052925 WO2019067594A1 (fr) 2017-09-27 2018-09-26 Sels de dérivés de pyrrolotriazine utiles en tant qu'inhibiteurs de tam

Publications (2)

Publication Number Publication Date
MA50655A MA50655A (fr) 2021-06-02
MA50655B1 true MA50655B1 (fr) 2021-11-30

Family

ID=63794769

Family Applications (1)

Application Number Title Priority Date Filing Date
MA50655A MA50655B1 (fr) 2017-09-27 2018-09-26 Sels de dérivés de pyrrolotriazine utiles en tant qu'inhibiteurs de tam

Country Status (33)

Country Link
US (3) US10633387B2 (fr)
EP (2) EP3988552A1 (fr)
JP (2) JP7504791B2 (fr)
KR (1) KR20200088308A (fr)
CN (1) CN111386273B (fr)
AU (2) AU2018342471B2 (fr)
BR (1) BR112020006145A2 (fr)
CA (1) CA3077308A1 (fr)
CL (2) CL2020000791A1 (fr)
CO (1) CO2020005009A2 (fr)
CR (1) CR20200179A (fr)
CY (1) CY1124952T1 (fr)
DK (1) DK3687996T3 (fr)
EC (1) ECSP20021655A (fr)
ES (1) ES2904458T3 (fr)
GE (1) GEP20227429B (fr)
HU (1) HUE057190T2 (fr)
IL (1) IL273579A (fr)
JO (1) JOP20200081A1 (fr)
LT (1) LT3687996T (fr)
MA (1) MA50655B1 (fr)
MD (1) MD3687996T2 (fr)
MX (1) MX2020003375A (fr)
PE (1) PE20210002A1 (fr)
PH (1) PH12020550143A1 (fr)
PL (1) PL3687996T3 (fr)
PT (1) PT3687996T (fr)
RS (1) RS62872B1 (fr)
SA (1) SA520411638B1 (fr)
SG (1) SG11202002821UA (fr)
SI (1) SI3687996T1 (fr)
TW (1) TWI821200B (fr)
WO (1) WO2019067594A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017035366A1 (fr) 2015-08-26 2017-03-02 Incyte Corporation Dérivés de type pyrrolo-pyrimidine utilisés comme inhibiteurs des tam
TWI753892B (zh) 2016-03-28 2022-02-01 美商英塞特公司 作為ｔａｍ抑制劑之吡咯并三嗪化合物
ES2975336T3 (es) 2016-12-22 2024-07-04 Novartis Ag Moduladores del receptor NMDA y usos de los mismos
MX2020003375A (es) 2017-09-27 2020-08-03 Incyte Corp Sales de inhibidores de macrofagos asociados a tumores (tam).
TWI832871B (zh) 2018-06-29 2024-02-21 美商英塞特公司 Axl/mer 抑制劑之調配物
PE20210948A1 (es) 2018-08-03 2021-05-24 Cadent Therapeutics Inc Moduladores del receptor nmda heteroaromatico y usos de los mismos
US20210275666A1 (en) 2020-03-06 2021-09-09 Incyte Corporation Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors
WO2022007921A1 (fr) * 2020-07-10 2022-01-13 北京范恩柯尔生物科技有限公司 Composé triazine, composition et utilisation associées
CN115028648B (zh) * 2021-03-03 2024-08-30 武汉誉祥医药科技有限公司 三并环化合物及其药物组合物和应用
EP4371978A1 (fr) * 2021-07-13 2024-05-22 Nippon Soda Co., Ltd. Procédé de production d'un composé uracile

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA02002938A (es) 1999-09-17 2004-12-06 Abbott Gmbh & Co Kg Inhibidores de cinasa como agentes agentes terapeuticos.
HU230396B1 (hu) 2000-06-28 2016-04-28 Smithkline Beecham Plc Nedves őrlési eljárás
WO2004035580A1 (fr) 2002-10-21 2004-04-29 Aprea Ab Reactivation de p53 de type sauvage dans des cellules tumorales humaines par un compose a faible poids moleculaire
WO2005025515A2 (fr) 2003-09-12 2005-03-24 California Institute Of Technology Inhibiteurs de la voie des proteasomes et methodes associees
UY28931A1 (es) 2004-06-03 2005-12-30 Bayer Pharmaceuticals Corp Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
AR053090A1 (es) 2004-07-20 2007-04-25 Osi Pharm Inc Imidazotriazinas como inhibidores de proteina quinasas y su uso para la preparacion de medicamentos
UY29177A1 (es) 2004-10-25 2006-05-31 Astex Therapeutics Ltd Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
SI1951724T1 (sl) 2005-11-17 2011-09-30 Osi Pharmaceuticals Llc Kondenzirani biciklični mTOR inhibitorji
PE20070855A1 (es) 2005-12-02 2007-10-14 Bayer Pharmaceuticals Corp Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
EP1957485B1 (fr) 2005-12-02 2013-02-13 Bayer HealthCare, LLC Derives substitues de 4-amino-pyrrolotriazine utiles dans le traitement de troubles hyperproliferatifs et de maladies associees a l'angiogenese
UA116187C2 (uk) 2005-12-13 2018-02-26 Інсайт Холдінгс Корпорейшн ГЕТЕРОАРИЛЗАМІЩЕНІ ПІРОЛО[2,3-b]ПІРИДИНИ Й ПІРОЛО[2,3-b]ПІРИМІДИНИ ЯК ІНГІБІТОРИ ЯНУС-КІНАЗИ
ES2562428T3 (es) 2005-12-15 2016-03-04 Rigel Pharmaceuticals, Inc. Inhibidores de cinasa y sus usos
MX2008013110A (es) 2006-04-12 2009-03-06 Vertex Pharma 4-5-dihidro-[1,2,4]triazolo[4,3-f]pteridinas como inhibidores de la proteina-cinasa plk1 para el tratamiento de trastornos proliferativos.
US20090253718A1 (en) 2006-04-25 2009-10-08 Astex Therapeutics Limited Pharmaceutical Compounds
WO2008045978A1 (fr) 2006-10-10 2008-04-17 Rigel Pharmaceuticals, Inc. Dérivés de pyrimidinediamine substitués par du pinane, utiles en tant qu'inhibiteurs de axl
EP2102210B1 (fr) 2006-12-14 2011-02-09 Vertex Pharmceuticals Incorporated Composés utilisables en tant qu'inhibiteurs de protéines kinases
PT2078010E (pt) 2006-12-29 2014-05-07 Rigel Pharmaceuticals Inc Triazoles substituídos com heteroarilos policíclicos úteis como inibidores de axl
EP2074115B1 (fr) 2006-12-29 2018-03-07 Rigel Pharmaceuticals, Inc. Triazoles substitués par n3-hétéroaryle et triazoles substitués par n5-hétéroaryle utiles comme inhibiteurs de axl
WO2008083353A1 (fr) 2006-12-29 2008-07-10 Rigel Pharmaceuticals, Inc. Triazoles à substitution aryle bicycliques et hétéroaryle bicycliques utiles en tant qu'inhibiteurs axl
WO2008098139A2 (fr) 2007-02-07 2008-08-14 The Regents Of The University Of Colorado Inhibiteurs des récepteurs axl à activité tyrosine kinase et procédés de fabrication et d'utilisation de ceux-ci
CA2695753A1 (fr) 2007-08-15 2009-02-19 Vertex Pharmaceuticals Incorporated Composes utilises comme inhibiteurs de proteines kinases
GB0719803D0 (en) 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
EP2215085B1 (fr) 2007-10-25 2011-09-07 AstraZeneca AB Dérivés de pyridine et de pyrazine utiles pour le traitement de troubles de la prolifération cellulaire
WO2009054864A1 (fr) 2007-10-26 2009-04-30 Rigel Pharmaceuticals, Inc. Triazoles substitués par aryle polycyclique et triazoles substitués par hétéroaryle polycyclique utiles comme inhibiteurs d'axl
WO2009085185A1 (fr) 2007-12-19 2009-07-09 Amgen Inc. Composés condensés de pyridine, de pyrimidine et de triazine en tant qu'inhibiteurs du cycle cellulaire
AR070127A1 (es) 2008-01-11 2010-03-17 Novartis Ag Pirrolo - pirimidinas y pirrolo -piridinas
EP2262772B8 (fr) 2008-04-16 2013-03-13 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Dérivés de quinolines utilisés comme inhibiteurs des kinases axl
AU2009271658B2 (en) 2008-06-23 2014-04-10 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors
JP5592884B2 (ja) 2008-07-09 2014-09-17 ライジェル ファーマシューティカルズ， インコーポレイテッド Ａｘｌ阻害剤として有用な多環式ヘテロアリール置換トリアゾール
PT2328888E (pt) 2008-07-09 2013-01-29 Rigel Pharmaceuticals Inc Triazóis bicíclicos em ponte substituídos com heteroarilos úteis como inibidores axl
WO2010014755A1 (fr) 2008-07-29 2010-02-04 The Regents Of The University Of Colorado Procédés et composés permettant d’optimiser le traitement contre le cancer
US20100075973A1 (en) 2008-08-28 2010-03-25 Takeda Pharmaceutical Company Limited Polo-like kinase inhibitors
AR074830A1 (es) 2008-12-19 2011-02-16 Cephalon Inc Pirrolotriazinas como inhibidores de alk y jak2
TW201041892A (en) 2009-02-09 2010-12-01 Supergen Inc Pyrrolopyrimidinyl Axl kinase inhibitors
JP5656976B2 (ja) 2009-04-29 2015-01-21 ローカス ファーマシューティカルズ インコーポレイテッド ピロロトリアジン化合物
TW201100429A (en) 2009-05-22 2011-01-01 Incyte Corp N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
SI2448938T1 (sl) 2009-06-29 2014-08-29 Incyte Corporation Experimental Station Pirimidinoni kot zaviralci pi3k
WO2011028685A1 (fr) 2009-09-01 2011-03-10 Incyte Corporation Dérivés hétérocycliques de pyrazol-4-yl-pyrrolo[2,3-d] pyrimidines en tant qu'inhibiteurs de janus kinase
NZ599342A (en) 2009-09-25 2014-04-30 Vertex Pharma Methods for preparing pyrimidine derivatives useful as protein kinase inhibitors
EP2311809A1 (fr) 2009-10-16 2011-04-20 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Quinolinyloxyphenylsulfonamides
US8604217B2 (en) 2009-11-12 2013-12-10 Selvita S.A. Compound, a process for its preparation, a pharmaceutical composition, use of a compound, a method for modulating or regulating serine/threonine kinases and a serine/threonine kinases modulating agent
AR079529A1 (es) 2009-12-18 2012-02-01 Incyte Corp Derivados arilo y heteroarilo sustituidos y fundidos como inhibidores de la pi3k
TWI643857B (zh) 2010-03-10 2018-12-11 英塞特公司 作為ｊａｋ１抑制劑之哌啶-４-基三亞甲亞胺衍生物
JP5752232B2 (ja) 2010-03-31 2015-07-22 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ プロテインキナーゼ阻害剤としての置換ピロロトリアジン化合物
CN102471342A (zh) 2010-05-05 2012-05-23 沃泰克斯药物股份有限公司 用作PKC-θ抑制剂的4取代的吡唑并吡啶类
EP2423208A1 (fr) 2010-08-28 2012-02-29 Lead Discovery Center GmbH Composants actifs pharmaceutiquement en tant qu'inhibiteurs Axl
RU2014118677A (ru) 2010-10-08 2015-11-20 Элан Фармасьютикалз, Инк. Ингибиторы киназ типа polo
ITRM20100537A1 (it) 2010-10-12 2012-04-12 Consiglio Nazionale Ricerche Aptamero inibitore del recettore tirosina chinasi axl per uso in terapia
JP5917545B2 (ja) 2010-11-19 2016-05-18 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｊａｋ阻害剤としてのシクロブチル置換ピロロピリジンおよびピロロピリミジン誘導体
WO2012068440A1 (fr) 2010-11-19 2012-05-24 Incyte Corporation Pyrrolopyridines et pyrrolopyrimidines à substitution hétérocyclique utilisées en tant qu'inhibiteurs des jak
JP5961187B2 (ja) 2010-12-20 2016-08-02 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｐｉ３ｋ阻害剤としてのｎ−（１−（置換フェニル）エチル）−９ｈ−プリン−６−アミン
ES2590778T3 (es) 2011-02-28 2016-11-23 Calitor Sciences, Llc Compuestos de quinolina sustituida
EP2688887B1 (fr) 2011-03-23 2015-05-13 Amgen Inc. Doubles inhibiteurs tricycliques fusionnés de cdk 4/6 et de flt3
ES2759615T3 (es) 2011-04-01 2020-05-11 Univ Utah Res Found Análogos de N-fenilpirimidina-2-amina sustituidos como inhibidores de la quinasa AXL
AR086983A1 (es) 2011-06-20 2014-02-05 Incyte Corp Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
CA2846652C (fr) 2011-09-02 2019-11-05 Incyte Corporation Heterocyclylamines en tant qu'inhibiteurs de pi3k
CN102408411B (zh) 2011-09-19 2014-10-22 北京康辰药业股份有限公司 一种含喹啉基的羟肟酸类化合物及其制备方法、以及含有该化合物的药物组合物及其应用
JP2014532060A (ja) 2011-10-03 2014-12-04 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 癌を治療するためのピロロピリミジン化合物
ES2614824T3 (es) 2011-11-14 2017-06-02 Ignyta, Inc. Derivados de uracil como inhibidores de la quinasa axl y c-met
US8993756B2 (en) 2011-12-06 2015-03-31 Merck Sharp & Dohme Corp. Pyrrolopyrimidines as janus kinase inhibitors
JP6006241B2 (ja) 2012-01-31 2016-10-12 第一三共株式会社 ピリドン誘導体
BR112014000049A2 (pt) 2012-03-27 2017-02-07 Bayer Ip Gmbh pirrolotriazinas substituídas com hidroximelilarilo e sua utilização
WO2013162061A1 (fr) 2012-04-26 2013-10-31 第一三共株式会社 Composé de pyrimidine bicyclique
US9193733B2 (en) 2012-05-18 2015-11-24 Incyte Holdings Corporation Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
AU2013312477B2 (en) 2012-09-06 2018-05-31 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
CN104995192A (zh) 2012-09-26 2015-10-21 加利福尼亚大学董事会 Ire1的调节
US9562047B2 (en) 2012-10-17 2017-02-07 The University Of North Carolina At Chapel Hill Pyrazolopyrimidine compounds for the treatment of cancer
CN104918945B (zh) 2012-11-01 2018-01-05 因赛特公司 作为jak抑制剂的三环稠合噻吩衍生物
CN104936963B (zh) 2012-11-20 2017-11-28 普罗齐纳斯有限公司 作为蛋白激酶抑制剂的硫醚衍生物
WO2014109858A1 (fr) 2013-01-14 2014-07-17 Amgen Inc. Méthodes d'utilisation d'inhibiteurs de cycle cellulaire pour moduler une ou plusieurs propriétés d'une culture cellulaire
TW201522337A (zh) 2013-03-12 2015-06-16 Arqule Inc 經取代之三環吡唑並－嘧啶化合物類
TWI649308B (zh) 2013-07-24 2019-02-01 小野藥品工業股份有限公司 喹啉衍生物
ES2685661T3 (es) 2013-11-08 2018-10-10 Ono Pharmaceutical Co., Ltd. Derivado de pirrolopirimidina
EP3102579B1 (fr) 2014-02-03 2019-04-10 Cadila Healthcare Limited Composés hétérocycliques
EP3233829B1 (fr) 2014-12-18 2019-08-14 Pfizer Inc Dérivés de pyrimidine et de triazine, et leur utilisation comme inhibiteurs d'axl
US9840503B2 (en) 2015-05-11 2017-12-12 Incyte Corporation Heterocyclic compounds and uses thereof
US9708333B2 (en) 2015-08-12 2017-07-18 Incyte Corporation Fused bicyclic 1,2,4-triazine compounds as TAM inhibitors
WO2017035366A1 (fr) 2015-08-26 2017-03-02 Incyte Corporation Dérivés de type pyrrolo-pyrimidine utilisés comme inhibiteurs des tam
US20180296561A1 (en) 2015-10-07 2018-10-18 The University Of North Carolina At Chapel Hill The Methods For Treatment Of Tumors
CN108137568A (zh) 2015-10-13 2018-06-08 日本农药株式会社 具有肟基的稠杂环化合物或其盐类及含有该化合物的农业园艺用杀虫剂以及其使用方法
WO2017083788A1 (fr) 2015-11-14 2017-05-18 Sunshine Lake Pharma Co., Ltd. Forme cristalline d'un composé de quinoline substituée et composition pharmaceutique en contenant
EP3373934B1 (fr) 2015-11-14 2020-05-20 Sunshine Lake Pharma Co., Ltd. Forme cristalline d'un composé de quinoléine substitué et compositions pharmaceutiques en contenant
TWI753892B (zh) 2016-03-28 2022-02-01 美商英塞特公司 作為ｔａｍ抑制劑之吡咯并三嗪化合物
US10166221B2 (en) 2016-04-22 2019-01-01 Incyte Corporation Formulations of an LSD1 inhibitor
WO2017223414A1 (fr) * 2016-06-24 2017-12-28 Incyte Corporation Composants hétérocycliques utilisés en tant qu'inhibiteurs de pi3k-y
JOP20170153A1 (ar) 2016-07-15 2019-01-30 Lilly Co Eli نظائر urocortin-2 جديدة معدلة بحمض دهني لعلاج داء السكري وأمراض الكلى المزمنة
RS63928B1 (sr) 2016-07-15 2023-02-28 Ionis Pharmaceuticals Inc Jedinjenja i metode za modulaciju smn2
MX2020003375A (es) 2017-09-27 2020-08-03 Incyte Corp Sales de inhibidores de macrofagos asociados a tumores (tam).
TWI832871B (zh) 2018-06-29 2024-02-21 美商英塞特公司 Axl/mer 抑制劑之調配物

Also Published As

Publication number Publication date
AU2018342471A1 (en) 2020-04-23
PT3687996T (pt) 2022-01-21
SI3687996T1 (sl) 2022-04-29
US20220227770A1 (en) 2022-07-21
ES2904458T3 (es) 2022-04-05
AU2018342471B2 (en) 2023-08-24
TWI821200B (zh) 2023-11-11
PE20210002A1 (es) 2021-01-05
PL3687996T3 (pl) 2022-02-21
JOP20200081A1 (ar) 2020-04-30
JP2024059647A (ja) 2024-05-01
IL273579A (en) 2020-05-31
ECSP20021655A (es) 2020-07-31
MX2020003375A (es) 2020-08-03
MD3687996T2 (ro) 2022-04-30
BR112020006145A2 (pt) 2020-10-20
JP2020535168A (ja) 2020-12-03
US10633387B2 (en) 2020-04-28
CR20200179A (es) 2020-11-02
LT3687996T (lt) 2022-01-10
TW201920186A (zh) 2019-06-01
HUE057190T2 (hu) 2022-04-28
CO2020005009A2 (es) 2020-05-29
US20190112313A1 (en) 2019-04-18
DK3687996T3 (da) 2022-01-10
SA520411638B1 (ar) 2024-03-28
EP3988552A1 (fr) 2022-04-27
WO2019067594A1 (fr) 2019-04-04
JP7504791B2 (ja) 2024-06-24
US20200347065A1 (en) 2020-11-05
CN111386273B (zh) 2024-06-14
PH12020550143A1 (en) 2020-12-07
CL2022001014A1 (es) 2022-11-18
CA3077308A1 (fr) 2019-04-04
SG11202002821UA (en) 2020-04-29
KR20200088308A (ko) 2020-07-22
RS62872B1 (sr) 2022-02-28
US11104682B2 (en) 2021-08-31
EP3687996B1 (fr) 2021-11-03
MA50655A (fr) 2021-06-02
CL2020000791A1 (es) 2020-09-25
CY1124952T1 (el) 2023-01-05
CN111386273A (zh) 2020-07-07
AU2023270198A1 (en) 2023-12-14
EP3687996A1 (fr) 2020-08-05
GEP20227429B (en) 2022-10-25

Similar Documents

Publication Publication Date Title
MA50655B1 (fr) Sels de dérivés de pyrrolotriazine utiles en tant qu'inhibiteurs de tam
MA41607B1 (fr) Sels d'un inhibiteur de pi3k et procédés de préparation de ces sels
CY1121338T1 (el) Χρηση αλατων του αναστολεα kinασης janus (r)-3-(4-(7h-πυρρολο[2,3-d]πυριμιδιν-4-υλο)-1η-πυραζολ-1-υλο)-3-κυκλοπεντυλο- προπανονιτριλιο
CR9272A (es) Amino-imidazolonas para la inhibicion de b-secretasa
ATE346070T1 (de) Purinderivate als kinaseinhibitoren
EA200800760A1 (ru) ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα
CR9244A (es) AMINO-IMIDAZOLONAS PARA LA INHIBICION DE ß-SECRETASA
EA201200669A1 (ru) ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα
ATE430747T1 (de) 2-pyrimidinyl-pyrazolopyridin-erbb- kinaseinhibitoren
EA201100580A1 (ru) Имидазопиридазинкарбонитрилы, используемые в качестве ингибиторов киназы
MA39172B1 (fr) Dérivés bicycliques hétérocycliques comme inhibiteurs de bromodomaines
EA201270553A1 (ru) Ингибиторы тирозинкиназы брутона
EA200801291A1 (ru) Карбониламинопирролопиразолы в качестве эффективных ингибиторов киназ
EA201070395A1 (ru) Ингибиторы polo-подобных киназ
ECSP056072A (es) Pirimidinonas sustituidas
DK1761520T3 (da) Kinaseinhibitorer
CL2021002656A1 (es) Compuestos de pirrolotriazina, inhibidores selectivos de proteínas quinasas kit y pdgfralfa; composición y uso.
EA201200891A1 (ru) Производные 3,4,4a,10d-тетрагидро-1h-тиопирано[4,3-c]изохинолина
MX2018008307A (es) Derivado de ascoclorina y uso del mismo como activador de proteina cinasa activada por adenosin monofosfato (ampk).
PE20170936A1 (es) Compuestos novedosos de imidazopiridazina y su uso
CY1122423T1 (el) Παραγωγα πυριμιδινης χρησιμα ως εκλεκτικοι αναστολεις jak3 kai/ή jak1
BR112022005895A2 (pt) Inibidores de aldose redutase para tratamento de deficiência de fosfomanomutase 2
EA202091588A1 (ru) Способ получения аминопиримидина и его промежуточных продуктов
MA46039B1 (fr) Dérivé de triazolopyrazinone utile en tant qu'inhibiteur de pde1 humain
EA200701815A1 (ru) 6-гетероарил-1,2,3,4,4а,10в-гексагидрофенантридины в качестве pde-4 ингибиторов для лечения воспалительных заболеваний